An advanced cancer detection platform from C2i Genomics (reportedly capable of spotting miniscule traces of the disease) recently landed $100m in funding.
A leader from the laboratory solutions provider talks about how the virus has created challenges for researchers, and how those obstacles might be cleared.
The science service and technologies firm plans to bring the CRO under its Laboratory Products and Services Segment umbrella after the deal is completed.
The Institute for Clinical and Economic Review will use Aetion observational real-world evidence to evaluate potential drugs from Takeda and CSL Behring.
The collaboration centers on development of precision cancer treatments, through discovery and validation of next-generation DNA damage response targets.
New research findings suggest that an immunotherapy assay enables determination of PD-L1 status in a high percentage of cancer patients and could guide personalized treatment selection.
The advanced biotech analysis company is harnessing the power of a formidable supercomputer to discover potential treatments for the virus and mutations.
A survey by the Pistoia Alliance indicates most professionals believe the tech can accelerate R&D, but companies are stymied by a skills gap and data bias.
The two major pharmaceutical firms have agreed to jointly develop and commercialize treatment combinations of lenacapavir and islatravir in HIV patients.
The IQVIA and NORD study shows rare-disease treatments account for only 11% of new drug spending, but 80% of orphan products treat rare diseases alone.
The company has increased capabilities at its Bend, Oregon location, including its SimpliFiH Solutions first-in-human services for small-molecule drugs.
The annual event, moved to the virtual realm thanks to COVID-19, offers content on remote monitoring, drug development technology and other key topics.
The US Food and Drug Administration (FDA) has issued guidance for companies developing vaccines, diagnostics and therapeutics against new variants of SARS-CoV-2.
The two companies will work to advance precision cancer medicine by harnessing genomics data in trial design, recruitment, site selection and other areas
A leader from the clinical data solutions firm explains how the challenges created by the pandemic have helped fuel creativity and innovation in studies.
In the drive to advance personalized medicine, researchers are increasingly turning to radiomics to assist in the discovery of new types of biomarkers.
The American Heart Association’s Heart of Communicating Science modules are designed to help experts break complex talk into easy-to-understand language.
William Gholston, with the Tampa Bay Buccaneers football team, is donating to the Moffitt Cancer Center to fund research into cancer treatment disparities.
California information technology and services company Syntegra and the National Institutes of Health (NIH) have signed a partnership to 'democratize access to the largest set of COVID-19 patient records': with the use of Syntegra's synthetic...
Sosei Heptares and PharmEnable will harness artificial intelligence-enabled technology and advanced chemistry to explore neurological disease solutions.
Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO.
The drug delivery platform company is exploring the viability of remdesivir and other potential treatments for the virus using its DehydraTECH technology.
The two organizations will collaborate on development of synthetic arms for clinical studies, drawing from millions of patient records and trial subject.
A leader from the IQVIA company explains how the boom in the volume and quality of data, and advanced analysis, can speed and streamline drug development.
A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.
Sanofi has made a new five-year, $25m partnership agreement with the World Health Organization (WHO) to fight Neglected Topical Diseases (NTD); and eliminate sleeping sickness by 2030.
OSP's free Digital Advances in Clinical Trial webinar (on December 9) will feature experts discussing recent advancements in the rapidly evolving field.
The online DNA network has delved into self-reported data of more than 563,000 US adults to help identify genetic risk of infection and severe outcomes.
Health tech specialists GoodCell are working with the New York Blood Center to identify COVID-19 patients with elevated risk of adverse clinical outcomes.
The federal agency has offered updates, advice and action regarding the COVID-19 pandemic, helping life-sciences professionals stay on top of developments.
